Biotechnological human antibody drug agent for use in the treatment of cancer and eye diseases
Product Properties:
- Recombinant human antibody structures that allow the human-compatible use of two anti-angiogenic recombinant antibodies (KDR1.3 and KDR2.6) for stopping tumor angiogenesis (formation of new blood vessels from existing ones)
Capabilities of Genetic Engineering and Biotechnology Institute:
- Recombinant human antibody library for human-compatible antibody development.
- Infrastructure and know-how on the development of recombinant human antibodies in the treatment of various diseases
- The efficacy of human antibody structures has been demonstrated by cell and mice models.
Patent:
The invention “Recombinant antibody structures that bind to and block the activity of Vascular Endothelial Growth Factor receptor 2/KDR”, which is used as a pattern in forming human antibody structures, has been registered with an international patent.
United States registration No.: 9193792, Registration date: 24/11/2015
China, registration No.: CN 1031190693 B, Registration date: 29/06/2016
Usage Area:
Pharmaceutical Industry